About This Comparison
Our Editorial Standards
This ro vs henry meds provider comparison is independently researched by our editorial team. We compare telehealth services based on publicly available information including pricing, available treatments, service areas, and verified customer reviews.
Not Medical Advice: This comparison is for informational purposes only. We are not healthcare providers. Always consult with a licensed physician before starting any treatment. Read our full medical disclaimer and editorial policy.
Ro vs Henry Meds: Complete GLP-1 Weight Loss Comparison (2025)
Choosing between Ro and Henry Meds for GLP-1 weight loss medication? Ro's live listing starts compounded semaglutide at $145/month (as of August 2026) and includes a free insurance check for brand-name coverage ($25-100/month typical copays when covered). Henry Meds' last-recorded price in our provider database is a flat $149/month with medication, supplies, and shipping included (May 2026) - Henry Meds isn't currently shown in our weight-loss rankings, so confirm current pricing directly. This comparison analyzes pricing, medications, and medical supervision.
Overview: Ro vs Henry Meds Weight Loss Comparison
Detailed Pricing Comparison: Insurance vs Cash-Pay
- Ro Insurance: $25-100/month copays (brand-name Wegovy/Zepbound), prior authorization required
- Ro Compounded: semaglutide from $145/month (as of August 2026); confirm dose-level and tirzepatide pricing at checkout
- Henry Meds: flat $149/month last recorded in our database (May 2026) - medication, supplies, and shipping included; not currently in our weight-loss rankings
- Data freshness: Ro's price is live and verified; Henry Meds' is last-recorded and may have changed - confirm before enrolling
- Best Value: Ro with insurance ($25-100/month copays); on last-recorded cash prices the two platforms sit within a few dollars ($145 vs $149)
- Both Accept: HSA/FSA cards for 25-35% effective tax savings
GLP-1 Medications: Brand-Name vs Compounded Formulations
- Semaglutide Efficacy: 14.9% average weight loss over 68 weeks in the STEP 1 trial (individual results vary)
- Tirzepatide Efficacy: up to 20.9% average weight loss over 72 weeks in the SURMOUNT-1 trial (individual results vary)
- Ro Medications: Brand-name (insurance) or compounded (cash-pay)
- Henry Meds: Compounded only, FDA-registered 503B pharmacies
- Dosing Schedule: Weekly injections, gradual dose escalation over 4-6 months
- Lifestyle Required: 500-750 calorie deficit + 150 min/week exercise for best results
Medical Consultation, Ongoing Support, and Monitoring
- Ro Consultation: online provider visit with on-demand coaching and support, per its listing
- Henry Meds Consultation: provider consultations included per its listing; free evaluation - you pay only if prescribed
- Blood Work: Both require baseline + quarterly monitoring
- Ro Labs: baseline blood work may be required; confirm arrangements and costs at checkout
- Henry Meds Labs: confirm lab requirements and any costs directly with Henry Meds
- Support details: both listings note provider support; confirm specifics with each platform before enrolling
Side Effects, Contraindications, and Safety Monitoring
- Common Side Effects: Nausea (30-50%), diarrhea, constipation, abdominal pain
- Serious Risks: Pancreatitis, gallstones, kidney injury (dehydration), hypoglycemia
- FDA Warnings: Thyroid C-cell tumors (rodent studies), gastroparesis/ileus
- Contraindications: Thyroid cancer history, MEN2 syndrome, pregnancy
- Discontinuation Rate: 5-10% stop due to intolerable side effects
- Emergency Support: Neither platform offers 24/7 emergency care
Customer Reviews and Real-World Results
- Henry Meds Rating: 9.0 (Excellent) in our ratings
- Ro Rating: 9.3 (Outstanding) in our ratings
- Average Weight Loss: 25-45 lbs over 6 months with lifestyle changes
- Best Results: 500+ cal deficit daily + 150+ min/week exercise
- Common Praise: Henry Meds support, Ro insurance navigation
- Common Complaints: Ro hidden fees, both platforms had 2023 shortages
How We Tested Ro vs Henry Meds
Our Comparison Methodology
This comparison is based on comprehensive analysis of GLP-1 weight loss protocols, insurance integration, pricing structures, and support models from both platforms, supplemented by peer-reviewed obesity medicine research.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved drug labels for Wegovy/Ozempic/Mounjaro/Zepbound, clinical literature on GLP-1 efficacy showing average weight loss of 14.9% (semaglutide, STEP 1) and up to 20.9% (tirzepatide, SURMOUNT-1); individual results vary, and peer-reviewed medical literature on GLP-1 mechanisms.
Research Foundation: We analyzed peer-reviewed studies including insurance coverage patterns, CMS Medicare Part D guidance on prior authorization requirements, compounding pharmacy regulations, and monthly check-in impact on adherence and outcomes.
Pricing Analysis: Pricing reflects the rates last recorded in our provider database; providers change prices frequently, so confirm current pricing directly at checkout. Total annual costs compared across insurance and cash-pay scenarios.
Service Verification: Platform capabilities, insurance acceptance, provider credentials, monthly check-in protocols, nutritional counseling, and lab coordination were evaluated through detailed review of each platform's published service information.
Our analysis is our own editorial work. Most of the providers compared here pay ManyTreatments a commission when you buy through a link on this page. Nobody pays us for a placement, a rating, or a listing, and we are not going to add that commissions have never influenced anything, because that is a claim about our own conduct we cannot show you evidence for. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Ro vs Henry Meds
For patients with insurance coverage, Ro provides unbeatable value at $25-100/month copays for brand-name Wegovy or Zepbound versus $300-1,400 retail costs. Ro's prior authorization navigation and insurance billing expertise justify choosing them over Henry Meds if your plan covers GLP-1 weight loss medications. However, approval is never guaranteed, and many insurance plans exclude coverage entirely.
Paying cash? The gap is smaller than it looks. Ro's compounded semaglutide starts at $145/month (as of August 2026), and Henry Meds' last-recorded flat rate is $149/month with medication, supplies, and shipping included (May 2026 - Henry Meds isn't currently shown in our weight-loss rankings, so confirm current pricing directly before enrolling). Henry Meds bundles its costs into one price with a free evaluation where you pay only if prescribed; Ro's live listing offers the broader medication menu, including brand-name Zepbound and Wegovy.
Weight loss potential comes from the medication itself (semaglutide or tirzepatide) rather than the platform prescribing it (individual results vary). Success depends on medication adherence, 500-750 calorie daily deficit, and 150+ minutes weekly exercise - not which platform prescribes the medication. Choose based on insurance coverage and preferred level of medical supervision, not expecting different clinical outcomes.
Frequently Asked Questions
Is Ro or Henry Meds better for GLP-1 weight loss?
Ro is better if you have insurance that covers Wegovy or Zepbound ($25-100/month copays vs $300-1,400 retail). Henry Meds may appeal if you want one flat bundled price: its last-recorded rate is $149/month with medication, supplies, and shipping included (May 2026). Henry Meds isn't currently shown in our weight-loss rankings, so confirm current pricing directly before comparing.
Which is cheaper: Ro or Henry Meds?
Ro is cheapest with insurance ($25-100/month copays). On cash-pay entry prices the two are nearly identical at last check: Ro's compounded semaglutide starts at $145/month (as of August 2026) and Henry Meds' last-recorded flat rate is $149/month including medication, supplies, and shipping (May 2026). Henry Meds isn't currently shown in our weight-loss rankings, so confirm its current pricing directly - and confirm dose-level costs on both platforms.
Do Ro and Henry Meds prescribe brand-name or compounded GLP-1s?
Ro offers both brand-name (Wegovy, Ozempic, Mounjaro, Zepbound) when insurance covers them, and compounded semaglutide/tirzepatide for cash-pay. Henry Meds offers only compounded GLP-1 medications from FDA-registered 503B pharmacies. Compounded versions use identical active ingredients at lower cost but lack brand-name convenience features like pre-filled pens.
How much weight can I lose with Ro or Henry Meds?
The medications are the same class at both platforms, and published trial results reflect the drug rather than the prescribing platform (individual results vary). In the STEP 1 and SURMOUNT-1 trials, semaglutide averaged 14.9% body weight loss over 68 weeks and tirzepatide up to 20.9% over 72 weeks (individual results vary).
Does insurance cover Ro or Henry Meds GLP-1 medications?
Ro accepts insurance and can bill brand-name Wegovy, Ozempic, Mounjaro, and Zepbound directly to your insurance carrier. Typical copays are $25-100/month but require prior authorization (3-14 day wait) and many plans exclude weight loss coverage entirely. Henry Meds does not accept insurance and operates on cash-pay only. Both accept HSA/FSA cards.
What are the side effects of GLP-1 medications from Ro or Henry Meds?
Side effects are identical regardless of platform since both use the same medications. Common: nausea (30-50%), vomiting, diarrhea, constipation, abdominal pain. Serious but rare: pancreatitis, gallstones, kidney injury from dehydration. 5-10% discontinue due to intolerable GI symptoms. Both platforms screen for contraindications but neither offers 24/7 emergency medical support.
Sources & References
Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.
- HealthIT.gov - Telehealth and TelemedicineOfficial HHS information on telehealth platforms and telemedicine
- PMC - Telemedicine Patient Outcomes StudyNIH PubMed Central research on telemedicine patient outcomes
- FDA Wegovy Prescribing InformationOfficial FDA-approved semaglutide prescribing information
- HHS - HIPAA Privacy StandardsHealth Insurance Portability and Accountability Act privacy regulations
- FDA - Semaglutide Safety InformationFDA safety information and warnings for semaglutide medications
- CMS - Medicare Part D Prior Authorization DataCenters for Medicare & Medicaid Services prescription drug authorization data
- IRS Publication 969 - HSA and FSA GuidelinesIRS rules for Health Savings Accounts and Flexible Spending Arrangements
- NEJM - Clinical StudyMedical research and clinical information
- GoodRx - Wegovy (Semaglutide) Drug InformationGoodRx drug guide for Wegovy semaglutide: uses, dosage, side effects, and cost
- FDA - GLP-1 Agonist Safety WarningsUpdated FDA warnings regarding GLP-1 agonist side effects and risks
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
